Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05330221 · ClinicalTrials.gov registry record · NA
Project 2: ACHIEVE- HF
A NA study of Hypertension and Heart Failure, sponsored by Henry Ford Health System.
- Recruiting
- Registry status
- NA
- Development phase
- 364
- Enrollment target
- 1
- Study location
NCT05330221: Recruiting NA study of Hypertension and Heart Failure, sponsored by Henry Ford Health System.
NCT05330221 is a NA study of Hypertension and Heart Failure that is actively recruiting participants, run by Henry Ford Health System. The registered enrollment target is 364 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05330221, a NA study of Hypertension and Heart Failure, is actively recruiting participants, sponsored by Henry Ford Health System.
- RECRUITING
- Registry status
- NA
- Development phase
- 364 participants
- Enrollment target
- 1
- Study location
Study Summary
This project is part of the ACHIEVE GREATER (Addressing Cardiometabolic Health In Populations Through Early PreVEntion in the GREAT LakEs Region) Center (IRB 100221MP2A), the purpose of which is to reduce cardiometabolic health disparities in two cities: Detroit, Michigan, and Cleveland, Ohio. The ACHIEVE GREATER Center involves four separate but related projects that aim to mitigate health disparities in risk factor control for three chronic conditions, hypertension (HTN, Project 1), heart failure (HF, Projects 2 and 4) and coronary heart disease (CHD, Project 3). The first three projects will involve the use of Community Health Workers (CHWs) to deliver an evidence-based practice intervention program called PAL2. Projects 1-3 also utilize the PAL2 Implementation Intervention (PAL2-II), which is a set of structured training and evaluation strategies designed to optimize CHW competence and adherence (i.e., fidelity) to the PAL2 intervention program. The present study is Project 2 of the ACHIEVE GREATER Center.
Primary Outcome
Change in systolic BP at 12-months vs. baseline (detect ≥ 5 mm Hg difference). This will be determined by comparing the "post-trial systolic BP" at 12-month mobile health unit (MHU) visit versus the "baseline systolic BP" at screening MHU visit.
Conditions Studied
Interventions
- BEHAVIORAL PAL2
- DRUG PHARM-PAL2
Study Locations (1)
Michigan
- Wayne State University - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 364 participants |
| Start Date | 2023-01-18 |
| Est. Completion | 2027-06-30 |
| Phase | NA |
What NCT05330221 shows while recruiting
NCT05330221 is an interventional study that assigns participants to a tested intervention. The registered 364 participants enrollment target is mid-sized for trials with a published cap, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which PAL2 is the first listed.
NCT05330221 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT05330221 about?
NCT05330221 is a clinical study titled "Project 2: ACHIEVE- HF". This project is part of the ACHIEVE GREATER (Addressing Cardiometabolic Health In Populations Through Early PreVEntion in the GREAT LakEs Region) Center (IRB 100221MP2A), the purpose of which is to reduce cardiometabolic health disparities in two cities: Detroit, Michigan, and Cleveland, Ohio. The A...
What is the current status of trial NCT05330221?
This trial is currently recruiting. It is a NA study. The enrollment target is 364 participants. The study started on 2023-01-18. Estimated completion is 2027-06-30.
What conditions does trial NCT05330221 study?
This clinical trial studies the following conditions: Hypertension, Heart Failure.
What interventions are being tested in trial NCT05330221?
The interventions under investigation include: PAL2 (BEHAVIORAL), PHARM-PAL2 (DRUG).
Who is sponsoring clinical trial NCT05330221?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05330221 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05330221's enrollment target sits among peer trials
364 156th of 470 higher than 315 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
How a Mediterranean Diet With Potatoes Impacts Heart and Metabolic Health in Adults With Pre-Diabetes
RECRUITING · NA
-
Conical Forearm and Cylindrical Upper Arm Non-Invasive Blood Pressure (NIBP) Measurements in Pregnant Patients
RECRUITING · NA
-
Comparing Healthcare Visit Recording and Open Notes to Improve Chronic iLlness Care Experience in Older Adults
RECRUITING · NA
-
Early Time-Restricted Eating in Older Adults With Hypertension
RECRUITING · NA
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04510597 · 364 participants · Phase 3
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
- NCT05098132 · 364 participants · Phase 1
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
- NCT05673148 · 364 participants · Phase 3
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
- NCT07094204 · 364 participants · Phase 1
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI